Clinical Trials Logo

Clinical Trial Summary

Colonization with imipenem-resistant Acinetobacter baumannii (IBA) is an unfavorable event for the patient, especially in intensive care. Indeed, it exposes the patient to the risk of developing serious infections, extremely difficult to treat. ABRI is a particularly resistant bacterium in the environment. When an ABRI epidemic occurs in a department as central to the hospital as a surgical resuscitation department, the control of such an event can be extremely complex. There are few clear and detailed descriptions in the literature of how to manage this type of outbreak, let alone an ABRI outbreak of this magnitude.


Clinical Trial Description

n/a


Study Design


NCT number NCT06173440
Study type Observational
Source University Hospital, Strasbourg, France
Contact Stéphanie DEBOSCKER, MD
Phone 33 3 69 55 03 10
Email stephanie.deboscker@chru-strasbourg.fr
Status Recruiting
Phase
Start date January 1, 2020
Completion date December 2023